HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Notably, MOF knockdown enhanced tolerance to TSA, a selective class I and II HDAC inhibitor, and has been used in treatment for a variety of tumors, such as cutaneous T-cell lymphoma, peripheral T-cell lymphoma (Mann et al., 2007; Sawas et al., 2015), and is currently in phase II clinical trials for HCC (Tsilimigras et al., 2018).